NORTH BRUNSWICK, N.J., Jan. 06, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma ...
Gelsolin is a multifunctional actin-binding protein that orchestrates cytoskeletal remodelling by severing, capping and nucleating filamentous actin in a calcium- and phosphoinositide-regulated manner ...
NORTH BRUNSWICK, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma ...
BioAegis Therapeutics believes that its lead product, recombinant human plasma gelsolin therapy (rhu-pGSN), is a viable therapeutic option for patients suffering from severe lung injury due to ...
Phase 2 proof-of-concept study for rhu-pGSN, a promising intervention across a spectrum of inflammatory diseases, to be studied as an intervention for the negative outcomes of decompression in SCUBA ...
We need new drugs to fight COVID-19 and other diseases. But our government’s approval process makes that too hard. This year’s pandemic got regulators to say they’ll speed the approval process. The ...
Please provide your email address to receive an email when new articles are posted on . Researchers found that a lower concentration of plasma gelsolin, or pGSN, was associated with more severe ...
But that's not enough. I know about the FDA's rules because my older brother, Dr. Thomas Stossel, discovered something that might save a lot of lives. Doing medical research at Harvard, he found a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results